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S EPSIS is a life-threatening systemic inflammatory dis-order, resulting from a harmful host response to invad-
ing pathogens or their toxins.1,2 After the onset of sepsis, 
an initial hyperactivation of the innate immune system 
takes place that persists for a few days, followed by a more 
protracted period of deleterious immunosuppression,3 pre-
dominantly characterized by defective adaptive immune 
mechanisms, including increased suppressive potency of 
regulatory T cells (Treg)
4 and myeloid derived suppressor 
cells.5,6 Recent studies have shown that the majority of 
deaths in sepsis occur during this immunoparalytic state 
due to persistent infections and general exhaustion of the 
patients’ organ systems.7,8
A growing body of evidence indicates that T cells play 
a pivotal role as mediators of sepsis-induced immunosup-
pression. Apoptotic T cell depletion,9,10 T cell exhaustion, 
which is characterized by a failure to produce cytokines and 
up-regulation of inhibitory surface proteins,11–14 and a shift 
from a predominantly proinflammatory TH1 to an antiin-
flammatory TH2 immune phenotype are the hallmarks of 
the aberrant adaptive immune responses in sepsis.15,16 How-
ever, the mechanisms driving these alterations still need to 
What We Already Know about This Topic
•	 Accumulating	 evidence	 points	 to	 immunosuppression	 as	 a	
contributor	to	development	and	progression	of	sepsis.
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ABSTRACT
Background: Immunosuppression has been recognized as a major cause of sepsis-related mortality. Currently, there is much 
interest in identifying central hubs controlling septic immunoparalysis. In this context, in this study, the authors investigate 
the role of microRNA-31 (miR-31) as a regulator of T cell functions.
Methods: Primary human T cells were separated from healthy volunteers (n = 16) and from sepsis patients by magnetic beads 
(n = 23). Expression of mRNA/microRNA (miRNA) was determined by real-time polymerase chain reaction. Gene silenc-
ing was performed by small interfering RNA transfection, and miRNA-binding sites were validated by reporter gene assays. 
Effects of miR-31 or anti-miR-31 transfection were analyzed by real-time polymerase chain reaction, Western blotting, and 
flow cytometry.
Results: Overexpression of miR-31 in stimulated CD4+ T cells promoted a proinflammatory phenotype with increased levels 
of interferon-γ (1.63 ± 0.43; P = 0.001; means ± SD) and reduced expression of interleukin (IL)-2 (0.66 ± 0.19; P = 0.005) 
and IL-4 (0.80 ± 0.2; P = 0.0001). In contrast, transfection of anti-miR-31 directed cells toward a TH2 phenotype. Effects on 
IL-2 and IL-4 were mediated by targeting of nuclear factor-kappa B–inducing kinase and factor-inhibiting hypoxia-inducible 
factor-1α. Interferon-γ, however, was influenced via control of signaling lymphocytic activation molecule (SLAM)-associated 
protein, an essential adaptor molecule of immunomodulatory SLAM receptor signaling, which was identified as a novel target 
gene of miR-31. In sepsis patients, an epigenetically driven down-regulation of miR-31 was found (0.44 ± 0.25; P = 0.0001), 
associated with increased nuclear factor-kappa B–inducing kinase, factor-inhibiting hypoxia-inducible factor-1α, SLAM-
associated protein expression, and a cytokine shift toward TH2.
Conclusions: In this study, the authors provide novel evidence of miR-31 as an emerging key posttranscriptional regulator of 
sepsis-associated immunosuppression. The study results contribute to a further understanding of septic immunoparalysis and 
provide new perspectives on miRNA-based diagnostic approaches. (Anesthesiology 2016; 124:908-22)
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be unveiled, and identification of molecular checkpoints and 
key regulatory molecules is a nascent field in sepsis research.
MicroRNAs (miRNAs) are small noncoding RNAs, 
which posttranscriptionally repress expression of target 
genes by base paring to their 3′ untranslated region (3′-
UTR).17 They are key participants in gene regulatory net-
works controlling virtually all cellular functions and play a 
crucial role in a plethora of diseases including cancer and 
inflammation.18–20 Recently, microRNA-31 (miR-31), a 
pleiotropically acting tumor suppressor miRNA,21,22 has 
been identified as a regulator of two strongly interrelated key 
transcription factor families, namely hypoxia-inducible fac-
tor (HIF)-1α and nuclear factor-kappa B (NF-κB). MiR-31 
activates the HIF pathway in human head and neck carci-
noma by targeting factor-inhibiting HIF-1α (FIH)23 and 
restricts the noncanonical NF-κB pathway in adult T cell 
leukemia by repressing NF-κB–inducing kinase (NIK).24
We assumed that miR-31 could be a molecular checkpoint 
of T cell functions because both HIF-1α and members of the 
NF-κB family of transcription factors have previously been 
identified as potent regulators of T cell–mediated immunity. 
Hypoxia, a prominent feature of most inflammatory processes, 
leads to stabilization of HIF-1α, which in turn promotes the 
induction of antiinflammatory mechanisms in human T cells.25–
27 Likewise, members of the NF-κB family are activated in 
response to inflammatory stimuli, relying on the canonical path-
way through activation of the inhibitor of kappa B kinase com-
plex or the noncanonical pathway via NIK, both resulting in the 
transcription of proinflammatory and antiapoptotic genes.28,29
In the current study, we show that miR-31, indeed, 
affects T cell functions. We demonstrate that transfection 
of miR-31 influences the balance of TH1/TH2 cytokine 
transcription by favoring a TH1 bias. This is accomplished 
by targeting FIH and NIK as well as by regulation of a 
newly identified miR-31 target gene, SH2D1A, encoding 
the intracellular adaptor molecule signaling lymphocytic 
activation molecule (SLAM)-associated protein (SAP). We 
further demonstrate that an activation-induced repression 
of miR-31 occurs in T cells of sepsis patients, which pro-
motes a shift from TH1 to TH2 cytokine transcription and 
thus contributing to the development of sepsis-induced 
immunosuppression.
Materials and Methods
Sepsis Patients and Healthy Controls
Blood samples were obtained between May 2009 and 
April 2012 from 23 sepsis patients (table 1) within 48 h 
after clinical diagnosis according to the criteria of the 
American College of Chest Physicians/Society of Critical 
Care Medicine consensus conference.30 Blood withdrawal 
was repeated after a time span of 24 h in case of seven 
enrolled patients who were diagnosed with early-stage 
sepsis (symptoms onset less than 4 h). Exclusion criteria 
were patients younger than 18 yr, prior antibiotic or cor-
ticosteroid treatment, immunodeficiency, and malignant 
diseases. Samples from 16 healthy volunteers who had 
been recruited between May 2009 and April 2012 in the 
context of the current and of two previously published 
studies31,32 were included as matched controls (table 1). 
All studies involving human subjects were approved by the 
Institutional Review Boards of the Ludwig Maximilian 
University of Munich, Munich, Germany (No. 107–11) 
and the University Hospital of Jena, Jena, Germany (No. 
2007-004333-42, local amendment for Munich Univer-
sity Hospital 2242-03/08). Written informed consent was 
received from all subjects or legal substitutes.
Purification of T Cells from Human Peripheral Blood
Peripheral blood mononuclear cells were isolated from EDTA 
blood (30 ml) by density gradient centrifugation (Histopaque 
1077; Sigma-Aldrich, Germany), and CD3+ or CD4+ T cells 
Table 1. Characteristics of Sepsis Patients and Healthy Controls
Sepsis Patients Healthy Controls
Number 23 16
Gender (female/male) 9/14 (39.1%/60.9%) 6/10 (37.5%/62.5%)
Age, yr (mean ± SD) 55.9 ± 18.0 40.5 ± 5.5
Positive blood culture 15 (65.2%)
Source of sepsis
  Pneumonia 8 (34.8%)
  Urinary tract infection 3 (13.0%)
  Intraabdominal infection 1 (4.4%)
  Central nervous system infection 6 (26.1%)
  Other 5 (21.7%)
Septic shock 9 (39.1%)
Interleukin-6 median (range), pg/ml 869 (30.8–59,434)
C-reactive protein median (range), mg/dl 15.5 (0.5–343.2)
Leukocyte median (range), /μl 13.2 × 103 (2.4–37.8 × 103)
Sequential organ failure score (mean ± SD) 11.0 ± 5.1
Nonsurvivors 7 (30.4%)
Healthy controls were nonsmoking individuals without history of acute or chronic infection, immunosuppressive diseases, or cancer.
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were subsequently enriched by negative selection using the 
Pan T cell isolation kit II or the CD4+ T cell isolation kit 
(Miltenyi Biotec, Germany), respectively. Cell number and 
viability were assessed by a ViCell analyzer (Beckman Coul-
ter, Germany). Purity of separated CD3+ and CD4+ T cells 
was determined by flow cytometry on an Attune Acoustic 
Focusing Cytometer (Life Technologies, Germany) and was 
more than 96% on average (Supplemental Digital Content 
1, fig. S1, http://links.lww.com/ALN/B247).
Cell Culture
Human Embryonic Kidney-293 cells (ECACC, United King-
dom) were grown in Dulbecco’s Modified Eagle’s Medium 
(Lonza, Switzerland), supplemented with 10% heat-inactivated 
Fetal Calf Serum (Biochrom, Germany), 1% non-essential 
amino acids (Biochrom), and 1% penicillin/streptomycin/L-
glutamine (Life Technologies). Primary T cells from healthy 
controls were cultured in Roswell Park Memorial Institute 
(RPMI)-1640 (Sigma-Aldrich) supplied with 10% heat-inac-
tivated Fetal Calf Serum, 1% HEPES (Sigma-Aldrich), and 
1% penicillin/streptomycin/L-glutamine (Life Technologies) at 
37°C and 5% CO2. For hypoxic conditions, cell cultures were 
maintained under a gas mixture of 3% O2 and 5% CO2 in an 
air-tight hypoxia chamber (Billups-Rothenberg, USA), which 
was then placed into a tissue culture incubator.
T Cell Stimulation Conditions
Purified CD3+ T cells from healthy controls were activated in 
24-well plates (1 × 106 in 1 ml of complete RPMI) with anti-
CD3/CD28 Dynabeads (Life Technologies) according to the 
manufacturer’s recommendations and harvested at the indicated 
time points. Enriched human CD4+ T cells were stimulated for 
the given periods of time in 12-well plates (1.5 × 106 in 1.5 ml 
of complete RPMI) with anti-CD3/CD28 Dynabeads or in 
96-well plates (0.2 × 106 in 0.2 ml of complete RPMI) using 
plate-bound anti-CD3 (5 μg/ml; clone OKT3) and soluble anti-
CD28 (5 μg/ml; clone CD28.2; both from BioLegend, USA).
Vector Constructs
The psiCHECK-2 vector (Promega, Germany) was used for 
creating SH2D1A 3′-UTR reporter constructs. In brief, the 
SH2D1A 3′-UTR was polymerase chain reaction (PCR) 
amplified from human genomic DNA (50 ng), using the 
following cycling conditions and the primers listed in table 
S1 (Supplemental Digital Content 1, http://links.lww.com/
ALN/B247) (Metabion, Germany): denaturation at 95°C 
for 5 min, 35 cycles of 95°C for 30 s, 64.6°C for 30 s, 72°C 
for 90 s, and a final elongation at 72°C for 5 min. The PCR 
product was ligated into the pSC-B amp/kan vector using the 
StrataClone Ultra Blunt PCR cloning kit (Stratagene, USA) 
and, subsequently, cloned downstream the Renilla luc reporter 
gene into the XhoI/PmeI restriction sites of the psiCHECK-2 
vector. Next, the two predicted hsa-miR-31-5p–binding sites 
in the SH2D1A 3′-UTR ( TargetScan Version 4.233) were 
sequentially eliminated using the QuikChange lightning 
site-directed mutagenesis kit (Stratagene) according to the 
manufacturer’s protocol. All reporter constructs were verified 
by sequence analysis (Eurofins MWG Operon, Germany).
Transient Transfection of Primary Human T Cells
Transient transfection of miRNA mimics and small interfering 
RNAs (siRNA) into CD4+ T cells was performed by electropor-
ation with the Neon Transfection System (Life Technologies). 
In brief, CD4+ T cells from healthy controls were transfected 
with 50 nM Ambion pre-miR-31-5p or scrambled control 
(both from Life Technologies), rested in complete RPMI-1640 
without antibiotics for 6 h and, subsequently, stimulated in 
12-well plates (1.5 × 106 in 1.5 ml of RPMI) with anti-CD3/
CD28 Dynabeads for 24 h. Gene silencing experiments were 
performed accordingly for up to 48 h with specific siRNAs 
directed against SH2D1A, FIH (both 50 nM), and NIK 
(100 nM) or with scrambled control (all ON-TARGETplus 
SMARTpool from GE Dharmacon, USA). For in vitro inhibi-
tion of hsa-miR-31-5p, purified CD4+ T cells of healthy donors 
were incubated in 96-well plates (0.2 × 106 in 0.1 ml of Accell 
delivery medium) with 1 μM of Accell miRNA inhibitor of 
hsa-miR-31-5p or scrambled control (GE Dharmacon) as per 
manufacturer’s recommendation and left untreated or stimu-
lated with anti-CD3/CD28 Dynabeads at a bead-to-cell ratio 
of 1:1 for 72 h. Successful transfection was determined by flow 
cytometry in case of (anti-)miRs, using Cy3-labeled pre-miR 
negative control (Life Technologies) and DY-547- labeled Accell 
miRNA inhibitor nontargeting control (GE  Dharmacon) or by 
quantitative polymerase chain reaction (qPCR) verification of 
target knockdown in case of siRNA transfection.
Luciferase Assay
Human Embryonic Kidney-293 cells were cotransfected by 
electroporation with the various SH2D1A 3′-UTR reporter 
plasmids (1 μg) containing the putative/mutated miR-31-
5p–binding sites as well as 50 nM pre-miR-31-5p or scram-
bled control and incubated in 12-well plates (0.15 × 106 in 
1 ml of complete Dulbecco’s Modified Eagle’s Medium with-
out antibiotics) for 48 h. Subsequently, firefly and renilla 
luciferase activities were quantified on a MicroLumat Plus 
instrument (Berthold Technologies, Germany) using the 
Dual Glo Luciferase Assay System (Promega).
RNA Extraction and complementary DNA Synthesis
Total RNA was extracted from purified CD3+ T cells or tran-
siently transfected CD4+ T cells using the miRVana miRNA 
isolation kit, the RNAqueous total RNA isolation kit or the 
RNAqueous-Micro total RNA isolation kit, respectively (all 
from Life Technologies), followed by DNAse-digest with 
the Turbo-DNA free kit (Life Technologies). Quantity and 
purity of the isolated RNA were determined using a Nano-
Drop 2000 spectrophotometer (Thermo Scientific, USA). 
complementary DNA was synthesized from 500 ng up to 
1 μg of total RNA using the SuperScript III First Strand 
 Synthesis System (Life Technologies).
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Quantitative Real-time PCR (qPCR)
All analyses were performed in duplicates on a Light Cycler 
480 instrument (Roche Diagnostics, Germany) as described 
in the study by Ledderose et al.31 In brief, quantification of 
mRNA expression was performed using Universal Probe 
Library probes (Roche Diagnostics), specifically designed 
primers (Probe Finder Software; Roche Diagnostics; primers 
synthesized by Metabion; see Supplemental Digital Content 
1, table S2, http://links.lww.com/ALN/B247) and the fol-
lowing cycling conditions: initial denaturation at 95°C for 
5 min, 45 cycles at 95°C for 10 s, 60°C for 30 s, and 72°C 
for 15 s. Succinate dehydrogenase subunit A and TATA Box 
Binding Protein were used as reference genes in all experi-
ments34 and relative mRNA expression was calculated with 
the Light Cycler Relative quantification software (Roche 
Diagnostics). To assess miR-31 expression, equal amounts of 
extracted total RNA (2 ng) were reversely transcribed using 
the TaqMan Micro RNA reverse transcription kit (Life Tech-
nologies). Endogenous miR-31 expression was subsequently 
determined by qPCR with U47 RNA as internal control, 
using a specific TaqMan Micro RNA Assay (Life Technolo-
gies) and applying the following cycling conditions: dena-
turation at 95°C for 10 min, 45 cycles of 95°C for 15 s, and 
60°C for 60 s.
Intracellular Staining and Flow Cytometry
For intracellular staining of SH2D1A, stimulated CD4+ T 
cells (0.2–0.5 × 106) of healthy donors were harvested at the 
indicated time points, washed twice with Hank balanced salt 
solution containing 1% bovine serum albumin and 0.01% 
sodium azide (both from Sigma-Aldrich) and stained for 
surface expression of CD4 (PerCP-conjugated anti-human 
CD4, clone RPA-T4; BioLegend) and CD25 (fluorescein 
isothiocyanate–conjugated anti-human CD25, clone BC96; 
BioLegend). Next, cells were fixed and permeabilized using 
the FoxP3/Transcription Factor Staining Buffer Set according 
to the manufacturer’s instructions (eBioscience, USA) and 
stained for intracellular expression of SH2D1A (phycoery-
thrin-conjugated anti-human SAP, clone XLP-1D12; eBio-
science). All analyses were performed on an Attune Acoustic 
Focusing Cytometer (Life Technologies) by sequential gat-
ing on lymphocytes, measuring 20,000 to 30,000 events per 
tube (Supplemental Digital Content 1, fig. S2, http://links.
lww.com/ALN/B247). Unstained, unstimulated, and iso-
type controls (from BioLegend and eBioscience) were used 
as gating controls.
Western Blot
For the preparation of whole cell extracts, primary CD3+ 
and CD4+ T cells of healthy controls were harvested, washed 
with ice-cold phosphate buffered saline and resuspended in 
150 μl of 1x cell lysis buffer plus 1x protease/phosphatase 
inhibitor cocktail (all from Cell Signaling, USA). Nuclear 
cell extracts were prepared using the nuclear extract kit 
(Active Motif, Belgium) according to the manufacturer’s 
instructions. Subsequently, cell lysates were vortexed, soni-
fied, and incubated on ice for 30 min. Total protein extracts 
were collected after centrifugation (10 min, 15,000g, 4°C), 
and protein concentration was determined by bicinchoninic 
acid assay (Thermo Scientific). Cell extracts (up to 15 μg 
protein) were separated on 8, 10, or 14% sodium dodecyl 
sulfate–polyacrylamide gel electrophoresis and blotted on 
polyvinylidene difluoride membranes. NIK and FIH pro-
teins were detected using rabbit polyclonal (NIK) or mono-
clonal (FIH, clone D19B3) antibodies, and SH2D1A was 
detected using rabbit polyclonal or rat monoclonal (clone 
XLP-1D12) antibodies (all antibodies from Cell Signaling). 
β-Actin (mouse monoclonal antibody, clone 8H10D10) 
or Lamin A (polyclonal antibody) were used as endog-
enous standards. Immunoreactive bands were subsequently 
detected using horseradish-labeled goat anti-mouse, goat 
anti-rabbit, or goat anti-rat antibodies (Cell Signaling). 
Image J (NIH; available at: http://rsbweb.nih.gov/ij/) was 
used for quantification of all Western blot bands.
Bioinformatics and Statistical Analyses
MicroRNA-31 target genes were identified on the basis of a 
stringent microRNA support vector regression score cutoff 
of −1.0 or lower35 by using the prediction programs Tar-
getScan, Probability of Interaction by Target Accessibility, 
and miRanda.33,36,37 Estimation of sample sizes was based on 
previous experience in the field of miRNA analysis. Gener-
ally, at least three independent experiments (i.e., n ≥ 3) were 
performed, and, with the exception of Western blot and flow 
cytometry analyses, all measurements were done in dupli-
cates (qPCR) or triplicates (transfection assays). Data were 
tested for normal distribution by using the Kolmogorov–
Smirnov and Shapiro–Wilk tests. Differences between 
groups were analyzed by using paired or unpaired Student’s 
t test (two tailed) in case of parametric distribution and two-
tailed Mann–Whitney U or Wilcoxon signed-rank test for 
nonparametric distribution. One-way ANOVA with Tukey 
multiple comparisons test was used to compare more than 
two groups. Pearson correlation coefficient (two-tailed test) 
was used to measure linear correlation in case of parametric 
distribution, whereas Spearman correlation coefficient (two-
tailed test) was used to determine measure linear correlation 
in case of nonparametric distribution. Statistical signifi-
cance was defined as a P value of less than 0.05 (*P < 0.05; 
** P < 0.001). If not stated otherwise, values given represent 
means ± SD. GraphPad Prism 6 software (GraphPad Soft-
ware, Inc., USA) was used for all analyses.
Results
T Cell Activation Leads to miR-31 Down-regulation
To explore the biological role of miR-31 in human T cells, 
we first assessed the expression kinetics of mature miR-31 
in human CD3+ T cells obtained from healthy volunteers 
after T cell receptor (TCR)–specific activation. As shown in 
 figure 1A, abundance of miR-31 remained largely unchanged 
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during the first 24 h after stimulation. Thereafter, a constant 
decline occurred resulting in a reduction of miR-31 expres-
sion by almost 50% after 72 h (54.3 ± 25.9; P  =  0.0036; 
fig. 1A). To gain insight into the underlying mechanisms, 
we measured the mRNA expression of SUZ12 and EZH2, 
which have recently been shown to epigenetically repress the 
Cy3-miR-transfected CD4+ T cells








































































































































Fig. 1. MicroRNA-31 (miR-31) is down-regulated in stimulated human T cells and impairs the balance of TH1/TH2 cytokine transcription. 
(A) CD3+ T cells were purified from peripheral blood of healthy donors (n = 4) and were left untreated or activated with anti-CD3/CD28 
Dynabeads for 16, 24, 48, and 72 h, respectively. Relative expression of mature hsa-miR-31-5p was quantified by quantitative polymerase 
chain reaction (qPCR) with U47 RNA as endogenous control. Data are means ± SD; *P = 0.038, 48 versus 0 h, and P = 0.036, 72 versus 0 h; 
§P = 0.0395, 48 versus 16 h, and P = 0.0168, 72 versus 16 h, in one-way ANOVA with Tukey post test. (B) Left panel presents rela-
tive SUZ12 and EZH2 mRNA levels at the indicated time points, as determined by qPCR in stimulated human T cells from A. Data 
are means ± SD; SUZ12: not significant (ns) P = 0.2954, 16 versus 24 h, *P = 0.0107, 24 versus 0 h, and P = 0.0352, 16 versus 0 h 
as well as EZH2: ns P = 0.9811, 16 versus 24 h, *P = 0.0022, 24 versus 0 h, and **P = 0.0008, 16 versus 0 h in one-way ANOVA 
with Tukey post test. Right panel depicts epigenetic regulation of miR-31 by polycomb repressive complex 2 (PRC2), consisting 
of the catalytic subunit EZH2 and three noncatalytic subunits SUZ12, RBAP48, and embryonic ectoderm development (latter two 
not shown). This complex is recruited to a genomic region (PRC response element [PRE]) upstream the miR-31 locus on chro-
mosome 9 (Chr 9p21.3), leading to miR-31 repression via chromatin silencing through histone H3 methylation (Met). (C, D) CD4+ 
T cells from healthy donors were transiently transfected with Cy3-labeled pre-miR scrambled control, Ambion pre-miR-31-5p, 
or pre-miR scrambled control, respectively, and stimulated for 24 h with anti-CD3/CD28 Dynabeads. (C) Transfection efficiency 
was determined by flow cytometry as the percentage of Cy3-fluorescent cell number in total cell number. Left panel shows rep-
resentative histogram, and right panel indicates calculated total transfection efficiency (open bar) of n = 3 individual experiments 
performed in triplicates. Data are means ± SD. (D) Total RNA was isolated from stimulated CD4+ T cells transiently transfected 
with Ambion pre-miR-31-5p or scrambled control. Relative interferon (IFN)-γ, interleukin (IL)-2, and IL-4 mRNA expression was 
measured by quantitative real-time PCR. Data represent means ± SD of n = 5 healthy donors. IFN-γ: *P = 0.001, IL-2: *P = 0.005, 
and IL-4: **P = 0.0001 in paired Student’s t test.
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Fig. 2. MicroRNA-31 (miR-31) regulates TH cytokine transcription via targeting nuclear factor-kappa B–inducing kinase (NIK) and 
factor-inhibiting hypoxia-inducible factor-1α (FIH). (A) CD3+ T cells from healthy donors (n = 3) were stimulated with anti-CD3/
CD28 Dynabeads and harvested at the indicated time points. Controls (labeled “-”) were left untreated (no anti-CD3/CD28 Dyna-
beads). Kinetics of NIK (left panel) and FIH (right panel) protein abundance were determined by Western blot analysis. One blot is 
representative of n = 3. Graphs above indicate fold induction (arbitrary units, normalized to β-actin–loading control) in relation to 
protein expression before stimulation. Data are means ± SEM. (B, C) CD4+ T cells of healthy donors (n = 5) were transiently trans-
fected with Ambion pre-miR-31-5p (miR-31) or pre-miR scrambled control (control), rested for 6 h and, subsequently, stimulated 
with anti-CD3/CD28 Dynabeads for 24 h. Relative NIK (B, left panel) and FIH mRNA (C, left panel) as well as protein expression 
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expression of miR-31.24,38 Concordantly, both transcripts 
sharply increased during the first 24 h after T cell stimulation 
(SUZ12: P = 0.0107; EZH2: P = 0.0022; fig. 1B). Collec-
tively, these data show an inverse relationship between T cell 
activation and endogenous miR-31 expression and strongly 
suggest functional relevance of this miR in human T cells.
Overexpression of miR-31 Impairs the Balance of  
TH1/TH2 Cytokine Transcription
To study the functions of miR-31 in primary human T 
cells, we transfected miR-31 mimic into CD4+ T cells of 
healthy donors and quantified gene transcription of the key 
T helper (TH) cytokines interleukin (IL)-2, IL-4, and inter-
feron (IFN)-γ in response to T cell stimulation. Transfection 
efficiencies were determined by flow cytometry in rela-
tion to mock-transfected CD4+ T cells of respective donors 
(32.53 ± 2.26%; fig. 1C). Overexpression of miR-31 reduced 
IL-2 and IL-4 mRNA levels by almost 35% (IL-2: 0.66 ± 0.19; 
P = 0.005) and 20% (IL-4: 0.80 ± 0.2; P = 0.0001), respec-
tively, whereas IFN-γ mRNA copies were markedly up-reg-
ulated (1.63 ± 0.43; P = 0.001; fig. 1D). Prompted by these 
results pointing to a central role of miR-31 in T cell–medi-
ated immunity, we next aimed to identify those miR-31 tar-
get genes accountable for the observed effects.
miR-31 Regulates TH Cytokine Transcription via Targeting 
NIK and Factor-inhibiting HIF-1α
In tumor cells, NIK/MAP3K14 and FIH/HIF1AN have 
previously been identified as miR-31 targets.23,24 Whether 
this functional relationship also exists in human T cells has 
not been investigated so far.
Assuming that—in case of regulation—activation-
induced decrease of miR-31 would result in higher protein 
expression of these direct miR-31 targets, we performed 
Western blot analyses on stimulated CD3+ T cell lysates of 
healthy donors. As shown in figure  2A, a 75-fold greater 
abundance of NIK (left panel) and a 10-fold greater 
abundance of FIH (right panel) was detectable in T cells 
activated for 3 days compared with untreated controls. To 
further confirm the hypothesis that NIK and FIH expres-
sion in human T cells is negatively regulated by miR-31, we 
analyzed mRNA and protein levels of both target genes after 
transfection of miR-31 mimic into CD4+ T cells of healthy 
donors. As shown in figure 2, B and C, overexpression of 
miR-31 led to substantial suppression of NIK and FIH 
transcripts (NIK: 0.75 ± 0.11, P = 0.0003; FIH: 0.64 ± 0.11; 
P < 0.0001; left panels) as well as of the corresponding pro-
teins (right panels).
Since both the NF-κB and HIF-1α pathways are involved 
in the orchestration of T cell responses,27 we next investigated 
whether the observed effects of miR-31 on TH cytokine pro-
duction are, at least partially, mediated by NIK and FIH. 
To this end, we performed siRNA-mediated knockdown 
experiments of either NIK or FIH in CD4+ lymphocytes 
of healthy donors and quantified the mRNA expression of 
IL-2, IL-4, and IFN-γ. To rule out the possibility that FIH-
mediated effects were potentially dampened by proteasomal 
degradation of HIF-1α in normoxia (21% O2), these experi-
ments were additionally performed under moderate hypoxic 
conditions (3% O2), thereby mimicking reduced oxygen 
tensions routinely encountered in lymphoid tissues.39,40 Spe-
cific knockdown of both target genes affected the expression 
of IL-2 mRNA similarly to miR-31: NIK silencing induced 
a repression of 36% (0.64 ± 0.09; P = 0.0001), whereas FIH 
silencing under hypoxic conditions led to a 27% reduc-
tion (0.73 ± 0.23; P = 0.0020; fig. 2D), thus supporting our 
hypothesis. Moreover, IL-4 transcripts decreased as a result of 
FIH knockdown both under normoxic and hypoxic condi-
tions (21% O2: 0.82 ± 0.21; P = 0.0239; 3% O2: 0.79 ± 0.24; 
P < 0.05; fig. 2E). Surprisingly, effects of miR-31 on IFN-γ 
mRNA expression could be mimicked by silencing of nei-
ther NIK nor FIH, respectively. Contrary to the previously 
observed up-regulation, IFN-γ mRNA expression was not 
influenced by silencing of NIK, whereas FIH knockdown 
led to reduced IFN-γ transcripts both under normoxic and 
hypoxic conditions (fig. 2F).
Conclusively, these findings suggest that miR-31 exerts its 
effects on IL-2 and IL-4 mRNA expression of human CD4+ 
cells by targeting NIK and FIH. However, both target genes 
were not accountable for the effects on IFN-γ transcription 
observed upon transfection of miR-31.
SH2D1A Is a Novel miR-31 Target and Modulates IFN-γ 
Expression in Human CD4+ T Cells
To find the missing link between miR-31 and IFN-γ mRNA 
expression, we used in silico analyses, which predicted 
SH2D1A as a promising candidate gene bearing two puta-
tive miR-31–binding sites with favorable prediction scores 
in its 3′-UTR (fig. 3A). SH2D1A encodes SAP, an intracel-
lular adaptor molecule involved in T cell–mediated immu-
nity. Because targeted mutation in the SH2D1A gene in 
murine T cells has been shown to result in enhanced IFN-γ 
Fig. 2. (Continued). (B and C, right panels) was detect-
ed by quantitative polymerase chain reaction (qPCR) 
and Western blot analysis, respectively. Data are pre-
sented as means ± SD. NIK: **P = 0.0003 and FIH: 
** P < 0.0001 in paired Student’s t test. One blot representative 
of n = 3 is shown. (D–F) CD4+ T cells, enriched from periph-
eral blood mononuclear cells of healthy donors (n = 3 to 7), 
were transiently transfected with specific small interfer-
ing RNAs (siRNAs) against NIK and FIH (open bars) or 
scrambled control and stimulated for up to 48 h under 
normoxic (21% O2) or hypoxic conditions (3% O2). Rela-
tive gene transcription of TH1/TH2 cytokines interleukin 
(IL)-2 (D), IL-4 (E), and interferon (IFN)-γ (F) was quantified 
by qPCR. Data are means ± SD. IL-2: NIK **P = 0.0001, 
FIH (21% O2) not significant (ns) P = 0.6357, FIH (3% O2) 
*P = 0.0020; IL-4: NIK ns P = 0.2981, FIH (21% O2) 
*P = 0.0239, FIH (3% O2) *P = 0.0116; IFN-γ: NIK ns 
P = 0.9253, FIH (21% O2) **P < 0.0001, FIH (3% O2) 
**P = 0.0005 in paired Student’s t test.
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Fig. 3. SH2D1A is a novel microRNA-31 (miR-31) target and modulates interferon (IFN)-γ expression in human CD4+ 
T cells. (A) Depiction of the genomic structure of the human SH2D1A gene on chromosome X and location of  putative 
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production,41,42 we hypothesized that the miR-31–induced 
up-regulation of IFN-γ in human T cells might be accom-
plished by repression of SH2D1A.
Once again, we performed Western blot analyses on CD3+ 
T cell extracts up to 72 h after stimulation with immobi-
lized anti-CD3 and soluble anti-CD28 and found increasing 
SAP expression kinetics strongly resembling those of NIK 
and FIH (fig. 3B). Flow cytometric analyses of stimulated 
CD4+ T cells showed that SAP expression strongly correlated 
with CD25, a surface marker of enhanced T cell activation 
(r = 0.84; P = 0.0006; fig. 3C, see upper panel for representa-
tive dot plots). Although SAP was detected in only 30% of 
resting CD4+ T cells (27.2 ± 3.7%; see graph in lower panel), 
65% of CD4+ T cells exhibited intracellular SAP after 3 days 
of stimulation (53.3 ± 11.7%; P = 0.0066). In line with these 
results suggesting that SH2D1A might also be a miR-31 tar-
get gene, transfection of miR-31 mimic into activated CD4+ 
T cells of healthy donors resulted in substantially reduced 
SH2D1A mRNA (0.59 ± 0.13; P < 0.0001; fig. 3D, left 
panel) as well as protein levels (right panel).
To provide experimental proof that SH2D1A is a bona 
fide target of miR-31, we performed luciferase reporter 
gene assays on vector constructs containing the full-length 
SH2D1A 3′-UTR. As shown in figure 3E, cotransfection of 
miR-31 mimic and wild-type SH2D1A 3′-UTR diminished 
luciferase activity by 80% compared with miR scrambled 
control (80.5 ± 9.5%; P = 0.0001). Dinucleotide exchanges in 
both seed match sequences partially restored luciferase activ-
ity to 60% (Mut 1 [Mutation seed match 1]: 57.7 ± 13.4%; 
P  =  0.0001) and 35% (Mut 2 [Mutation seed match 2]: 
34.4 ± 2.2%; P  =  0.0001), respectively, whereas mutation 
of both binding sites completely abolished the observed 
miR-31 effect on reporter gene expression (Mut 1 + 2: 
106.7 ± 23%; P = 0.8298). Thus, our data prove that miR-
31 directly regulates SH2D1A expression by binding to the 
identified target sites in its 3′-UTR.
Having demonstrated a functional relationship between 
miR-31 and SH2D1A, we next turned to the question 
whether miR-31 up-regulates IFN-γ transcription via 
repression of SH2D1A. Therefore, we analyzed IFN-γ 
transcripts in stimulated CD4+ T cells after transfection 
of siRNA directed against SH2D1A or scrambled control. 
In accordance with our hypothesis, qPCR demonstrated 
significantly increased IFN-γ mRNA levels (1.25 ± 0.21; 
P = 0.002; fig. 3F), whereas both IL-2 and IL-4 remained 
largely unaffected. Hence, our data indicate that miR-31 
modulates IFN-γ transcription in primary human CD4+ T 
cells through the newly identified target gene SH2D1A.
Reduced Expression of miR-31 in T Cells of Sepsis 
Patients Is Associated with Target Gene Up-regulation and 
Modulates Transcription of TH1 and TH2 Cytokines
Based on our results suggesting that miR-31 directs CD4+ T 
cells toward a TH1 phenotype, it appeared likely that miR-31 
also exerts major influence on T cell responses during sepsis. 
Fig. 3. (Continued). miR-31-5p–binding sites in its 3′- 
untranslated region (3′-UTR). The SH2D1A gene com-
prises four exons (E1-E4); the coding sequence (CDS) is 
marked by a red box, ending with a 1769-nt UTR. Target 
prediction algorithms identified two putative miR-31–bind-
ing sites, indicated by bold blue lines with positions and 
seed sequences given below. (B) Kinetics of SH2D1A/sig-
naling lymphocytic activation molecule–associated pro-
tein (SAP) protein expression were evaluated by Western 
blot analysis in anti-CD3/CD28 stimulated CD3+ T cells of 
healthy donors (n = 3). One representative blot is shown; 
the graph above denotes fold induction (arbitrary units, 
normalized to β-actin–loading control) in relation to protein 
expression before stimulation. Data are means ± SEM. (C) 
CD4+ T cells from healthy donors (n = 3) were left untreat-
ed or stimulated with plate-bound anti-CD3 and soluble 
anti-CD28 for 24, 48, and 72 h. Cells were analyzed for 
expression of surface CD25 as well as intracellular SAP 
by flow cytometry. Upper panel graph: correlation of SAP 
and CD25 expression; Pearson r = 0.84; P = 0.0006. Low-
er panel graph: kinetics of SAP expression in stimulated 
CD4+ T cells of all three donors. Data are means ± SD. 
*P = 0.0064, 48 versus 0 h, and P = 0.0066, 72 versus 0 h, 
§P = 0.0143, 48 versus 24 h, and P = 0.0272, 72 versus 24 h 
in one-way ANOVA with Tukey post test. Representative 
plots and histograms of one donor are shown, with individ-
ual stains performed in duplicates. All plots are gated on 
“live” cells, as determined by forward/side scatter proper-
ties. Percentages are means ± SD. Percentage increase 
of SAP in relation to unstimulated cells (0 h) denoted as 
ΔSAP means ± SD. (D) CD4+ T cells of healthy donors 
(n = 5) were transiently transfected with Ambion pre-miR-
31-5p (miR-31) or pre-miR scrambled control (control) 
and, subsequently, stimulated with anti-CD3/CD28 Dy-
nabeads for 24 h. Relative SH2D1A mRNA (left panel) as 
well as protein (right panel) expression was measured by 
quantitative polymerase chain reaction and Western blot 
analysis. Data are presented as means ± SD. **P < 0.0001 
in paired Student’s t test. One blot representative of n = 3 
is shown. (E) The SH2D1A 3′-UTR containing the putative 
mir-31–binding sites was cloned into the psiCHECK-2 re-
porter vector. Control constructs lacking either one (Mut 1: 
binding site 1, Mut 2: binding site 2) or both (Mut 1 + 2) of 
the miR-31–binding sites were generated by site-directed 
mutagenesis. Wild-type (WT) SH2D1A 3′-UTR (open bar) 
as well as mutant controls (shaded gray bars) were co-
transfected with Ambion pre-miR-31-5p into Human Em-
bryonic Kidney-293 cells, and hRLuc reporter activity was 
determined relative to WT SH2D1A 3′-UTR cotransfected 
with pre-miR-scrambled control (control, black bar). Data 
are expressed as means ± SD of n = 9 to 18 experiments. 
**P < 0.0001: WT versus control, Mut 1 versus control, Mut 
2 versus control; §§P < 0.0001 Mut 1 versus WT, Mut 1 + 
2 versus WT; &P = 0.0187 Mut 2 versus Mut 1 in one-way 
ANOVA with Tukey post test. (F) Relative mRNA expres-
sion of TH1/TH2 cytokines interleukin (IL)-2, IL-4, and IFN-γ 
was quantified in CD4+ T cells transiently transfected with 
specific small interfering RNA (siRNA) directed against 
SH2D1A (open bars) or with scrambled control and stimu-
lated for 48 h. Data are means ± SD of n = 6 healthy donors. 
IL-2: not significant (ns) P = 0.9533; IL-4: ns P = 0.9833; 
IFN-γ: *P = 0.002 versus control in paired Student’s t test. 
FITC = fluorescein isothiocyanate.
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To address this issue, we quantified miR-31 abundance in 
CD3+ T cells of sepsis patients enrolled within 48 h after 
diagnosis as well as in unstimulated samples of healthy con-
trols (table 1). As depicted in figure 4A, miR-31 expression 
was reduced by more than 50% in CD3+ T cells of sepsis 
patients when compared with healthy controls (0.44 ± 0.25; 
P = 0.0001; fig. 4A). Moreover, a weak inverse correlation 
between miR-31 and the patients’ initial Sequential Organ 
Failure Assessment43 scores was found (Supplemental Digital 
Content 1, table S2, http://links.lww.com/ALN/B247). To 
explore the kinetics of miR-31 during the initial phase of 
sepsis, we reassessed its expression 24 h after the first mea-
surement in patients who had been diagnosed with early-
stage sepsis. Of note, when compared with donors with 
late sepsis (i.e., blood samples were obtained within up to 
48 h after clinical diagnosis), these patients displayed higher 
miR-31 expression at the time of the first quantification 
(Supplemental Digital Content 1, fig. S3, http://links.lww.
com/ALN/B247). Interestingly, however, miR-31 expres-
sion continued to decrease in the respective patients as sep-
sis persisted (P = 0.0051; fig. 4B). Simultaneously, SUZ12 
(left panel) and EZH2 (right panel) transcripts increased 
(SUZ12: P  =  0.022; EZH2: P  =  0.0469; fig. 4C), which 
indicates epigenetic regulation of miR-31 in primary human 
T cells during sepsis.
We reasoned that the miR-31 down-regulation occurring 
in sepsis might induce alterations in TH cytokines contrary 
to those observed after transfection of miR-31 mimic. To 
provide experimental proof, we transfected miR-31 hair-
pin inhibitor (anti-miR-31) into CD4+ T cells of healthy 
donors. Targeting and transfection efficiency in resting 
and in stimulated CD4+ T cells were tested by qPCR (rest-
ing: 0.27 ± 0.13; P < 0.0001; anti-C3/CD28: 0.48 ± 0.24; 
P < 0.0001; fig. 5A, left panel) and flow cytometry, respec-
tively (fig. 5A, see right panel for representative histogram). 
We then analyzed mRNA levels of the miR-31 target genes 
NIK, FIH, and SH2D1A following transfection of anti-
miR-31 or scrambled control. As expected, we detected a sig-
nificant increase in all three target genes (NIK: 1.73 ± 0.44; 
P  =  0.0061; FIH: 1.32 ± 0.44, P  =  0.0465; SH2D1A: 
1.30 ± 0.11; P = 0.0024; fig. 5B). In line with these results, 
we found significantly increased IL-2 and IL-4 mRNA 
expression in stimulated CD4+ T cells (IL-2: 2.23 ± 0.20; 
P < 0.0001; IL-4: 1.53 ± 0.32; P = 0.0113; fig. 5C), whereas 














































































































































Fig. 4. MicroRNA-31 (miR-31) is down-regulated in T cells of 
patients with sepsis. (A) Total RNA was extracted from puri-
fied CD3+ T cells of sepsis patients (n = 23, sepsis) within 48 h 
after clinical diagnosis as well as from CD3+ T cells of healthy 
donors (n = 16, control). Relative expression of endogenous 
miR-31-5p was quantified by quantitative polymerase chain 
reaction (qPCR) using U47 RNA as normalizing control. Left 
panel shows scatter dot plot with each symbol representing 
data from one subject. Horizontal lines delineate means ± SD. 
Right panel indicates fold reduction of miR-31 in T cells of the 
same sepsis patients versus healthy controls. Data are given 
as means ± SD. **P = 0.0001 in unpaired Student’s t test. 
(B) Blood withdrawal was repeated after a time span of 24 h in 
case of seven patients who were diagnosed with early-stage 
sepsis (symptom onset less than 4 h) and miR-31 expression 
was reanalyzed in CD3+ T cells of these individuals by qPCR. 
 
Fig. 4. (Continued). Zero and 24 h indicate blood collection 
and T cell separation at the time of diagnosis as well as 24 h 
later. Symbols with connecting lines represent data of individ-
ual subjects at the time of diagnosis (0 h) as well as 24 h later. 
*P = 0.0051 in paired Student’s t test. (C) Relative mRNA levels 
of polycomb group proteins SUZ12 (left panel) and EZH2 (right 
panel) were quantified in the same samples by qPCR. SUZ12: 
*P = 0.022 in paired Student’s t test and EZH2: *P = 0.0469 in 
Wilcoxon signed-rank test. SDHA = succinate dehydrogenase 
subunit A; TBP = TATA Box Binding Protein.
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Finally, we set out to explore whether these in vitro 
findings could be transferred to the clinical setting found 
in sepsis. In fact, we detected increased mRNA levels of 
NIK (P = 0.9375; fig. 6A), FIH (P = 0.0184; fig. 6B), and 
SH2D1A (P = 0.0466; fig. 6C) in the majority of early-stage 
sepsis patients 24 h after initial quantification at the time 
of clinical diagnosis. Concordantly, most of these patients 
exhibited an increase in IL-2 (fig. 6D) and IL-4 (fig. 6E) 
transcription and a decrease in IFN-γ mRNA levels within 
24 h (fig. 6F).
Taken together, our data show that reduction of miR-31 
in T cells during the early phase of sepsis modulates TH1/
TH2 cytokine expression toward TH2 via up-regulation of 
the miR-31 target genes NIK, FIH, and SH2D1A.
Discussion
Research over the past decades mainly focused on the early 
proinflammatory phase of sepsis. However, recent studies 
indicate a paradigm shift in the conception of sepsis patho-
physiology as they stress that a later and therefore more pro-
tracted stage of immunoparalysis plays a detrimental role in the 
morbidity and mortality of the disease. Among the multiple 
cellular mechanisms driving sepsis-induced immunosuppres-
sion, T cell pathologies such as cellular dysfunction, apoptotic 
depletion, and altered patterns of differentiation have been 
identified as key elements. However, no data on molecular 
pathways directing these alterations have been reported so far.
In this study, we identify miR-31 as an important novel con-
stituent of the regulatory networks modulating the TH1/TH2 
equilibrium in human sepsis: miR-31 safeguards the balance 
of pro- and antiinflammatory responses of human CD4+ T 
cells by supporting TH1 cytokine transcription and prevent-
ing a TH2 bias via repression of FIH, NIK, and the newly 
identified target gene SH2D1A, thereby influencing the 
networks of HIF-1α, NF-kB, and SLAM receptor signal-
ing. In sepsis, an epigenetically driven down-regulation of 
miR-31 expression promotes a CD4+ T cell shift toward a 
TH2 phenotype via up-regulation of these target genes, thus 
facilitating the transition from a hyperinflammatory to an 
immunoparalytic state.
In neoplastic development and tumor metastasis, miR-31 
was previously shown to be an endogenous negative regula-
tor of FIH23 and NIK,24 thereby activating the HIF-1α and 
restricting the noncanonical NF-κB pathway. Since both sig-
naling pathways are highly interrelated with inflammatory 
processes, these studies have led us to assume a role for miR-
31 as a regulator of T cell functions.
In fact, we found that in vitro activated T cells of healthy 
donors exhibit significantly diminished miR-31 levels 
when compared with unstimulated controls and that per-
sistent stimulation of the TCR provoked a steady decline 
in miR-31 abundance, suggesting that expression of miR-
31 is closely related to the T cell activation status. In vitro 
overexpression of miR-31 in stimulated human CD4+ T 
cells induced a proinflammatory phenotype with increased 
levels of IFN-γ mRNA and reduced transcription of IL-2 
and IL-4. These cytokines play prominent roles in the com-
plex networks of immune responses during sepsis. Whereas 






























































































Fig. 5. AntimicroRNA-31 (anti-miR-31) inhibits the previously observed miR-31 effects in purified T cells of healthy donors. 
(A) Purified CD4+ T cells of healthy donors (n = 4) were incubated with Accell anti-miR-31-5p (open bars) or a DY-
547-labeled scrambled control for 72 h with (+) and without (−) stimulation with anti-CD3/CD28 Dynabeads. Suc-
cessful transfection was confirmed by quantitative polymerase chain reaction (left panel) as well as by flow cytom-
etry (right panel). Data are means ± SD. **P < 0.0001 in paired Student’s t test. Histogram is representative of n = 3 
individual experiments performed in duplicates. (B, C) Relative mRNA levels of the miR-31 target genes nuclear fac-
tor-kappa B–inducing kinase (NIK), factor-inhibiting hypoxia-inducible factor-1α (FIH), and SH2D1A (B) as well as of the 
TH1/TH2 cytokines interferon (IFN)-γ, interleukin (IL)-2, and IL-4 (C) were quantified in CD4
+ T cells of healthy donors after 72 h of incu-
bation with Accell anti-miR-31-5 (open bars) or scrambled control in the absence (in case of target genes) or presence (in case of cyto-
kines) of anti-CD3/CD28 Dynabeads. Data are means ± SD of n = 3 to 4 independent experiments. NIK: *P = 0.0061; FIH: *P = 0.0465; 
SH2D1A: *P = 0.0024; IFN-γ: not significant (ns) P = 0.1136; IL-2: *P < 0.0001; IL-4: *P = 0.0113 in paired Student’s t test.
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differentiation to activate immune effector cell functions 
and to mediate pathogen clearance during the initial hyper-
inflammatory septic response,44–46 antiinflammatory IL-4 
induces TH2 polarization as well as suppression of macro-
phage and neutrophil activities in the immunosuppressive 
stage of sepsis.47,48 IL-2, however, plays an essential role in 
both pro- and antiinflammatory reactions during inflam-
matory disorders, promoting lymphocyte proliferation49 as 
well as limiting excessive immune responses in autoimmune 
diseases such as myasthenia gravis50 and diabetes mellitus.51
When investigating whether the interaction of miR-31 with 
NIK and FIH may be responsible for the observed effects on 
the cytokine profiles of CD4+ T cells, we found the functional 
miR-31-NIK and miR-31-FIH relationship to be maintained 
in human T cells. Surprisingly, only the miR-31 effects on IL-2 
and IL-4 could be attributed to targeting of these two target 
genes. In line with results of previously published studies,52–54 
knockdown of NIK induced a profound reduction in IL-2 
transcription. In hypoxia, a hallmark of inflammation,55 the 
observed effect on IL-2 expression, is additionally enforced by 
miR-31–mediated repression of FIH. Moreover, knockdown 
of FIH resulted in substantial reduction of IL-4 mRNA levels, 
which is in accordance with previous findings reporting that 
activated HIF-1α–deficient murine splenocytes produce more 
IL-4.26 Unexpectedly, neither NIK nor FIH targeting could 
account for the miR-31–induced up-regulation of IFN-γ.
In silico analysis predicted two miR-31–binding sites with 
favorable scores suggesting SAP to be the missing link between 
miR-31 and IFN-γ regulation. SAP is the gene product of 
SH2D1A and is known to activate many signaling pathways 
downstream of the SLAM family of immune cell receptors, 
CD150 (SLAM), CD229 (Ly9), CD244 (2B4), CD84 
(SLAMF5), NK-T-B antigen (SLAMF6), and CD319 (CD2-
like receptor activating cytotoxic cell).56,57 Engagement of 
SLAM receptors influences cytokine expression, for example, 
IFN-γ production,56 and results in initiation of T cell–medi-
ated signals such as protein kinase C-θ and NF-κB activa-
tion.41 Moreover, mutations in SAP have been demonstrated 
to lead to enhanced IFN-γ levels upon T cell stimulation.41,42 
In the present study, we provide several lines of evidence that 
SH2D1A is a bona fide target of miR-31 and that the effect 
of miR-31 on IFN-γ expression in primary CD4+ T cells is 
mediated via miR-31-SH2D1A regulation. First, lucifer-
ase reporter gene assays with wild-type and mutant vectors 
demonstrated that miR-31 negatively regulates the SH2D1A 
3′-UTR. In addition, exogenous overexpression of miR-31 
in primary human T cells led to substantially reduced levels 
of SAP expression. Second, T cell activation substantially 
increased SAP abundance in T cells of healthy donors, dis-
playing expression kinetics resembling those of the miR-31 
targets FIH and NIK, and third, siRNA targeting of SH2D1A 
resulted in enhanced IFN-γ transcription. Taken together, 
these data establish an miR-31/NIK/FIH/SAP nexus that 
modulates human CD4+ T cell functions via the HIF-1α, 
NF-κB, and SLAM receptor signaling pathways.
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Fig. 6. Reduced expression of microRNA-31 (miR-31) in 
T cells of sepsis patients is associated with target gene 
up-regulation and modulates transcription of TH1 and TH2 
cytokines. (A–F) Relative mRNA expression of the miR-31 
target genes nuclear factor-kappa B–inducing kinase (NIK) 
(A), factor-inhibiting hypoxia-inducible factor-1α (FIH) (B), 
and SH2D1A (C) as well as transcription of TH1 and TH2 cy-
tokines interleukin (IL)-2 (D), IL-4 (E), and interferon (IFN)-γ 
(F) were analyzed in the CD3+ T cell samples of those seven 
patients (S1–S7) diagnosed with early sepsis at the time of 
diagnosis (0 h) and 24 h later (24 h). (A–C) Symbols with con-
necting lines represent data of individual subjects at 0 and 
24 h. Not significant (ns) in Wilcoxon signed-rank test (NIK, 
P = 0.9375); *in paired Student’s t test (FIH, P = 0.0184; SH2D1A, 
P = 0.0466). (D–F) Raw data of relative cytokine mRNA 
expression for each subject diagnosed with early sepsis 
(S1–S7) at the time of diagnosis (0 h, black bars) as well as 
24 h later (24 h, open bars). SDHA = succinate dehydroge-
nase subunit A; TBP = TATA Box Binding Protein.
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When examining T cells of sepsis patients enrolled up 
to 48 h after clinical diagnosis, we found that endogenous 
expression of miR-31 was significantly reduced when com-
pared with healthy controls. This is consistent with previous 
studies reporting diminished levels of miR-31 in T cells of 
patients with systemic lupus erythematosus58 as well as in 
peripheral blood mononuclear cells of patients diagnosed 
with influenza A.59 After lowering the level of miR-31 in 
CD4+ T cells of healthy donors by use of a miR-31 hairpin 
inhibitor to mimic septic conditions, increased transcription 
of NIK, FIH, and SH2D1A could be detected, which was 
associated with enhanced IL-2 and IL-4 as well as decreased 
IFN-γ levels. This underlines the validity of our analysis and 
provides further insight into the impact of mir-31 in sepsis. 
Noteworthy, in patients diagnosed with early-stage sepsis, a 
further substantial decrease in miR-31 abundance occurred 
within 24 h after the initial quantification. These decreasing 
kinetics were accompanied by an increase in NIK, FIH, and 
SH2D1A gene expression. Moreover, the majority of early-
stage sepsis patients displayed increased IL-2 and IL-4 as well 
as reduced IFN-γ mRNA expression, potentially favoring an 
antiinflammatory TH2 bias such as typically occurs during 
the immunosuppressive phase of the disease.
Our findings regarding miR-31–mediated cytokine kinet-
ics in T cells of early-stage sepsis patients are in accordance 
with a previous study showing that the early phase of sepsis 
is characterized by a combination of T cell apoptosis and 
simultaneous T cell proliferation,60 a process that necessar-
ily depends on IL-2 secretion. Moreover, increased levels of 
both IL-4 and other antiinflammatory cytokines have been 
repeatedly described during sepsis,61,62 potentially driving 
the development and persistence of immunosuppression.47 
In this context, Boomer et al.7 have demonstrated that T cells 
of sepsis patients produce significantly less IFN-γ upon TCR 
stimulation, which has been associated with both restricted 
TH1 differentiation
46 and reduced macrophage activation.44 
Thus, our results point out a strong impact of miR-31 kinet-
ics in endogenously activated T cells of sepsis patients.
As a potentially underlying mechanism leading to 
repression of miR-31 in activated T cells, we identified 
markedly up-regulated gene transcription of the poly-
comb group (PcG) proteins EZH2 and SUZ12. Being 
core components of the polycomb repressive complex 2, 
EZH2 and SUZ12 are involved in numerous pathophysi-
ological processes, promoting transcriptional repression 
and influencing cell fate regulation via histone meth-
ylation.63–65 MiR-31 has been shown to be epigenetically 
regulated by the PcG proteins EZH2 and SUZ12 both in 
adult T cell leukemia24 and in melanoma cells,38 generally 
resulting in apoptosis resistance and tumor progression. 
Therefore, recent focus has been laid on targeting PcG 
proteins as a novel treatment option in cancer.66 In the 
current study, we now show that PcG-mediated negative 
regulation of miR-31 might also influence critical inflam-
matory responses in sepsis.
Mortality in sepsis still ranges between 30 and 50%.1,2 
Failure of former therapeutic approaches has led to a re-
evaluation of conceptions regarding sepsis pathophysiology, 
which laid new focus on the immunosuppressive phase of the 
disease. Due to the diversity of mechanisms influencing adap-
tive immune responses during sepsis, identification of hubs 
controlling these inflammatory processes is rather challeng-
ing. Taken together, we here provide novel evidence of miR-
31 as an emerging key posttranscriptional regulator of TH2 
skewing in human sepsis, which contributes to sepsis-asso-
ciated immunosuppression. Reduced expression of miR-31 
in T cells of sepsis patients induces up-regulation of the 
miR-31 targets NIK, FIH, and SH2D1A, thus favoring an 
immunosuppressive TH2 bias of T cell differentiation. Our 
data suggest clinical relevance of these functional relation-
ships in sepsis patients and point out miR-31 expression in 
T cells to be a potential biomarker to monitor the develop-
ment and prevalence of sepsis-associated immunodeficiency. 
The implications of these early findings will now have to be 
tested in a larger-scale study with a particular focus on the 
role of miR-31 in septic CD4+ T cells to confirm the mecha-
nistic associations proposed here.
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